2010—2024年美国毒物中心报告的儿童赛拉嗪暴露特征分析
该研究基于美国毒物中心国家毒物数据系统(NPDS),对2010年1月至2024年12月报告的0—19岁儿童和青少年赛拉嗪相关暴露进行回顾性描述性分析。共纳入109例暴露,多数发生在2022—2024年;年龄分布为0—5岁57例(52.3%)、6—12岁4例(3.7%)、13—19岁48例(44.0%)。36例(33.0%)为单纯赛拉嗪暴露,73例(67.0%)合并至少一种其他物质,最常见为芬太尼55例(50.5%)。单纯赛拉嗪暴露最常见临床效应为中枢神经系统抑制15例(41.7%)和心动过缓4例(11.1%);赛拉嗪合并芬太尼暴露最常见为中枢神经系统抑制44例(80.0%)和呼吸抑制38例(69.1%)。6例死亡均发生在赛拉嗪与芬太尼共用的情况下。作者结论认为儿童赛拉嗪相关暴露相对少见,临床医生须对非法药物供应中的掺杂物(包括赛拉嗪可能重新出现)保持警惕。
要点
- 儿童赛拉嗪暴露共109例,多数发生在2022—2024年,13—19岁占44.0%(48例),0—5岁占52.3%(57例)。
- 67.0%(73例)为赛拉嗪合并至少一种其他物质,最常见合并芬太尼55例(50.5%)。
- 单纯赛拉嗪暴露最常见效应为中枢神经系统抑制15例(41.7%)和心动过缓4例(11.1%)。
- 赛拉嗪合并芬太尼暴露最常见效应为中枢神经系统抑制44例(80.0%)和呼吸抑制38例(69.1%)。
- 6例死亡全部发生在赛拉嗪与芬太尼共用的情况下。
适用人群与场景
- 0—19岁儿童和青少年中报告至美国毒物中心国家毒物数据系统(NPDS)的赛拉嗪相关暴露,时间范围为2010年1月至2024年12月。
红旗征与不能漏的情况
- 赛拉嗪合并芬太尼暴露的患儿可出现中枢神经系统抑制(44例,80.0%)和呼吸抑制(38例,69.1%),6例死亡均发生在赛拉嗪与芬太尼共用的情况下。
研究设计与关键结果
- 研究类型为回顾性描述性分析,数据来自美国毒物中心国家毒物数据系统(NPDS),纳入2010年1月至2024年12月0—19岁赛拉嗪相关暴露共109例。
- 暴露随时间增加,多数发生在2022—2024年;年龄分布为0—5岁57例(52.3%)、6—12岁4例(3.7%)、13—19岁48例(44.0%)。
- 36例(33.0%)为单纯赛拉嗪暴露,73例(67.0%)为赛拉嗪合并至少一种其他物质;最常见合并物质为芬太尼55例(50.5%)。
- 单纯赛拉嗪暴露最常见临床效应为中枢神经系统抑制15例(41.7%)和心动过缓4例(11.1%)。
- 赛拉嗪合并芬太尼暴露最常见临床效应为中枢神经系统抑制44例(80.0%)和呼吸抑制38例(69.1%)。
- 6例死亡,全部发生在赛拉嗪与芬太尼共用的情况下。
证据类型、等级与局限
- 证据类型:基于美国毒物中心国家毒物数据系统(NPDS)的回顾性描述性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,基于NPDS数据,儿童赛拉嗪相关暴露相对少见;临床医生须对非法药物供应中的掺杂物(包括赛拉嗪可能重新出现)保持警惕。
- 原文讨论指出,儿童单纯赛拉嗪暴露的临床效应与其他α2受体激动剂大致相似;与成人暴露相反,在某些儿科人群中芬太尼暴露的医学后遗症可能因赛拉嗪共用而加重。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Xylazine is an alpha-2 adrenergic receptor agonist not approved for use in humans. Xylazine has been increasingly found in the United States illegal drug supply and has been detected in fentanyl-associated overdose deaths. There are limited data on xylazine exposures in the pediatric population.
METHODS: Data were obtained from America's Poison Centers® National Poison Data System® (NPDS), a near real-time surveillance system that collects data from poison centers across the US. A retrospective descriptive analysis was performed for xylazine-associated exposures reported to National Poison Data System® from January 2010 to December 2024 in children and teenagers ages 0-19 years.
RESULTS: There were 109 xylazine-associated exposures. Exposures increased over time, with most occurring during 2022-2024. The age distribution of xylazine-associated exposures included 57 (52.3%) among ages 0-5 years, four (3.7%) among ages 6-12 years, and 48 (44.0%) among ages 13-19 years. Thirty-six (33.0%) exposures were coded as xylazine only and 73 (67.0%) as xylazine plus at least one co-occurring substance. The most commonly coded co-exposure was fentanyl 55 (50.5%). Among exposures to xylazine only, the most common clinical effects were central nervous system (CNS) depression 15 (41.7%) and bradycardia four (11.1%). Among exposures to xylazine plus fentanyl, the most common clinical effects were CNS depression 44 (80.0%) and respiratory depression 38 (69.1%). Six patients died, all in the setting of xylazine co-occurring with fentanyl.
DISCUSSION: In the pediatric population, the clinical effects of exposure to xylazine only are grossly similar to those of other alpha-2 agonists. Contrary to exposures in adults, the medical sequelae of fentanyl exposure may be worsened by xylazine co-exposure in some pediatric populations. The limitations of this study are discussed.
CONCLUSIONS: Based on National Poison Data System® data, pediatric xylazine-related exposures are relatively uncommon. Clinicians must remain vigilant for adulterants, including the possible re-emergence of xylazine, in the illegal drug supply.
参考来源
- Dernbach MR, Yeh M, Schier J, et al. Characterizing pediatric xylazine exposures reported to United States poison centers, 2010-2024. Clin Toxicol (Phila). 2026. PMID: 41837951. doi:10.1080/15563650.2026.2636639
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。